Incidence and disease burden of bronchiectasis in systemic lupus erythematosus: a nationwide population-based study in Korea Authors: Geonhui Min, Dong Eun Kye, Heajung Lee, Yeonghee Eun, Hyung Koo Kang, Hayoung Choi, Bumhee Yang, Hyun Lee Published: 2026 ABSTRACT AbstractObjectivesPulmonary abnormalities, such as interstitial lung disease, have been relatively well studied in patients with systemic lupus erythematosus (SLE). However, it remains unclear whether the risk of bronchiectasis and its associated disease burden are increased in SLE.MethodsUsing the Korean National Health Insurance Service dataset, we conducted a population-based matched cohort study involving adults aged ≥20 years diagnosed with SLE (SLE cohort) between 2002 and 2012 and a 1:4 age, sex and health insurance service-matched cohort (matched controls). Beginning 1 year after enrolment, participants were followed until the date of a bronchiectasis diagnosis, death or 31 December 2019, whichever came first.ResultsDuring a median follow-up of 12.8 years (IQR 10.0–16.0 years), the incidence rate of bronchiectasis was higher in the SLE cohort than in the matched controls (374.8 vs 236.2/100 000 person-years, p<0.001). The SLE cohort showed a 1.46-fold (95% CI 1.22 to 1.76) increased risk of developing bronchiectasis compared with the matched cohort. Within the SLE cohort, age older than 40 years (highest adjusted HR (aHR) in those ≥70 years 25.08, 95% CI 7.62 to 82.53) and asthma (aHR 1.73, 95% CI 1.11 to 2.70) were associated with an increased risk of bronchiectasis. In contrast, obesity was inversely associated with the risk of bronchiectasis (aHR 0.56, 95% CI 0.38 to 0.82). Individuals with SLE who developed bronchiectasis had significantly higher rates of mortality, emergency department visits and hospitalisations than those who did not develop bronchiectasis.ConclusionsThe risk of bronchiectasis was higher in individuals with SLE than in controls, and its development was associated with a worse disease course, higher mortality during follow-up and increased healthcare utilisation.Keywords: Lupus Erythematosus, Systemic; Incidence; Epidemiology; Autoimmune Diseases WHAT IS ALREADY KNOWN ON THIS TOPIC Pulmonary complications such as interstitial lung disease are well documented in systemic lupus erythematosus (SLE), but population-based evidence regarding the association between SLE and bronchiectasis remains limited. Pulmonary complications such as interstitial lung disease are well documented in systemic lupus erythematosus (SLE), but population-based evidence regarding the association between SLE and bronchiectasis remains limited. WHAT THIS STUDY ADDS This nationwide cohort study indicates that individuals with SLE have an increased risk of developing bronchiectasis compared with matched controls. This nationwide cohort study indicates that individuals with SLE have an increased risk of developing bronchiectasis compared with matched controls. The association remains consistent when accounting for potential overlap with other connective tissue diseases. The association remains consistent when accounting for potential overlap with other connective tissue diseases. Within the SLE population, certain demographic and clinical factors are associated with higher bronchiectasis risk. Within the SLE population, certain demographic and clinical factors are associated with higher bronchiectasis risk. Patients with SLE with bronchiectasis also experience increased healthcare utilisation. Patients with SLE with bronchiectasis also experience increased healthcare utilisation. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings highlight the importance of proactive respiratory monitoring in patients with SLE. These findings highlight the importance of proactive respiratory monitoring in patients with SLE. Early recognition of bronchiectasis may facilitate timely interventions to prevent disease progression and improve long-term outcomes in this vulnerable population. Early recognition of bronchiectasis may facilitate timely interventions to prevent disease progression and improve long-term outcomes in this vulnerable population. Introduction Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterised by diverse clinical manifestations and fluctuating disease activity.1 2 Pulmonary involvement occurs in up to 50%–70% of patients with SLE and encompasses pleuritis, pulmonary hypertension, diffuse alveolar haemorrhage and interstitial lung disease (ILD).3 4 Although lung parenchymal involvement in ILD in SLE has been well characterised—with documented effects on morbidity and long-term outcomes—the full spectrum of SLE-related respiratory complications remains incompletely defined. Bronchiectasis is a chronic respiratory disease defined radiographically by irreversible bronchial dilatation and clinically by chronic cough, sputum production and recurrent respiratory infections. It is associated with persistent airway inflammation and may result in substantial morbidity and mortality.5 Connective tissue diseases (CTDs), such as rheumatoid arthritis (RA) and systemic sclerosis, have been shown to be associated with an elevated bronchiectasis risk.6 7 Furthermore, when CTDs and bronchiectasis coexist, the prognosis is worse than when either disease is presented independently.8 9 Although those findings suggest that systemic inflammation and immune dysregulation in CTDs might contribute to airway damage, no association between SLE and bronchiectasis has been clearly elucidated. Although several case reports and small-scale cohort studies have reported the occurrence of bronchiectasis in patients with SLE,10,12 large-scale population-based studies investigating such an association remain rare. Furthermore, it is not known whether the presence of bronchiectasis significantly affects the natural disease course of SLE. Clarifying this relationship is important to inform surveillance strategies and early interventions that could preserve lung health in patients with SLE. To address this gap, we conducted a nationwide, population-based, matched-cohort study using the Korean National Health Insurance Service (NHIS) database. We compare the risk of incident bronchiectasis in adults with SLE with that in matched controls, identify SLE-specific risk factors for bronchiectasis and evaluate the effects of bronchiectasis on mortality and healthcare utilisation. Methods Data source and setting This study used the Korean NHIS-National Sample Cohort (NHIS-NSC) database, a representative population-based retrospective cohort in Korea. The NHIS-NSC database has data on: (1) demographic variables (age and sex); (2) socioeconomic variables (eg, type of insurance, residential area); (3) healthcare utilisation (outpatient department visits, emergency department (ED) visits and hospitalisations); (4) health screening examination findings (eg, body mass index (BMI), smoking status and alcohol consumption) and (5) disease diagnoses based on the International Classification of Diseases, 10th Revision (ICD-10), medical treatment, procedures and surgery.13 Various epidemiological studies for bronchiectasis that relied extensively on NHIS data have already been published.14,18 Study population Between 1 January 2002 and 31 December 2012, the database contains data for 554 804 adults aged ≥20 years. After excluding missing values in variables required for cohort selection or analysis (complete-case analysis) (n=26 178) and those diagnosed with SLE between 1 January 2002 and 31 December 2002 (n=255), we identified 528 371 SLE-naïve adult participants. Among them, individuals with a diagnosis of bronchiectasis prior to enrolment (n=5090), those who developed bronchiectasis within the 1-year washout period (n=1368) and those who died during the washout period (n=750) were excluded. Consequently, 521 163 bronchiectasis-naïve adults were included in the analysis. Of them, 3368 participants were diagnosed with SLE (SLE cohort), and the remaining 517 795 had no diagnosis of SLE (non-SLE control cohort), defined as individuals who did not receive an SLE diagnosis throughout the entire follow-up period. The index date (t0) was defined as the date of the first SLE diagnosis for the SLE cohort and the date of the earliest general health examination during 2002–2012 for the matched controls. To establish a matched cohort, 1:4 propensity score matching was performed based on age, sex and type of insurance, resulting in a matched cohort of 13 472 individuals without SLE. For the matched non-SLE cohort, follow-up began on the date of the earliest general health examination during 2002–2012. Participants were followed up until death, a bronchiectasis diagnosis or 31 December 2019, whichever occurred first (figure 1). Flow chart of study participants. SLE, systemic lupus erythematosus. Exposure SLE was defined as the presence of a major or minor diagnostic code associated with ICD-10 code M32 and a special registration code (V136) provided by the Rare Intractable Diseases (RID) programme of the NHIS.3 The RID programme of the NHIS in Korea provides significant financial support for patients with SLE, covering up to 90% of their medical costs. Registration requires a strict government review, ensuring that only eligible patients are approved. In addition, specialists in internal medicine must assign the official diagnostic code before enrolment, which guarantees clinical accuracy. This dual system of administrative screening and specialist verification minimises misdiagnosis and makes the programme highly reliable. As a result, the RID programme reduces the economic burden on patients and generates trustworthy data for national research and policy development. Outcomes Our major study outcome was the risk of bronchiectasis in individuals with SLE versus controls. Bronchiectasis was defined using the ICD-10 diagnosis code J47.19 Our minor study outcomes were to identify risk factors for bronchiectasis in the SLE cohort and compare the disease burden of individuals with SLE according to the presence or absence of bronchiectasis. As the disease burden, we considered healthcare utilisation (ED visits and hospital admissions) and mortality. All-cause and respiratory-related death were evaluated using data from Statistics Korea (an initiative of the Ministry of Strategy and Finance, Republic of Korea).20 Respiratory-related healthcare utilisation was defined as ED visits or hospitalisations with ICD-10 codes for any respiratory system disease (J00–J99) as a major or minor diagnosis. Respiratory disease-related mortality was defined as death with a primary diagnosis coded under ICD-10 codes J00–J99.21 Covariates The following covariates were considered in the analysis: demographic factors (age, sex, income level and insurance type), lifestyle factors (smoking status, alcohol consumption and physical activity), comorbidities, the Charlson Comorbidity Index (CCI) and medication history. Baseline covariates were defined at the index date. Comorbidities, CCI and medication history were assessed using claims data prior to the index date to ensure appropriate temporal ordering. BMI was calculated as weight (kg) divided by the square of height (m) and classified according to the recommendations for Asians as follows: underweight (<18.5 kg/m2), normal (18.5–22.9 kg/m2), overweight (23.0–24.9 kg/m2) and obese (≥25.0 kg/m2). Smoking status was classified as people who had never smoked, people who previously smoked, and people who currently smoke.22 Economic status was classified as high income (80th–100th percentile), middle income (40th–80th percentile) and low income (<40th percentile). The type of insurance was classified as self-employed health insurance or employee health insurance. Alcohol consumption and physical activity were categorised based on the number of days per week of alcohol consumption and physical activity participation, respectively.23 CCI was calculated by observing comorbidities during the preceding year. Medication use was assessed for systemic corticosteroids and immunomodulators (azathioprine, mercaptopurine, ciclosporin, tacrolimus and methotrexate). Systemic corticosteroid use was defined as prescriptions for ≥2 consecutive weeks within 1 year prior to the index date (t0) and immunomodulator use was defined based on prescription records within the same period. Comorbidities were identified based on the following ICD-10 codes: asthma (J45–J46)24,26; chronic obstructive pulmonary disease (J42–J44, except J43.0 (unilateral emphysema))27,30; cerebrovascular disease (I60–I69); cardiovascular disease, including hypertension (I10–I15); angina or myocardial infarction (I20–I25); heart failure (I43, I50, I09.9, I11.0, I25.5, I13.0, I13.2, I42.0, I42.5–I42.9 and P29.0); diabetes mellitus (E10–E14)31,34 and CTDs other than SLE (M05–M06, M33–M34, M315, M351, M353 and M360).7 8 35 Statistical analysis Categorical variables are presented as numbers (percentages), and we used the χ2 test to compare groups. Continuous variables are presented as means (SD) or medians (IQRs), and we used the t-test or Mann-Whitney U test to compare groups. We used the incidence rate of bronchiectasis, which is calculated as the number of incident events per 100 000 person-years (PY), to compare the SLE and matched cohorts. The cumulative incidence of bronchiectasis between the SLE and matched cohorts was compared using a cumulative incidence curve and Gray’s test. Univariable and multivariable Cox proportional hazards regression analyses were conducted to estimate the HR and corresponding 95% CI for incident bronchiectasis in the SLE cohort, compared with the matched cohort. Model 1 was a crude model. Model 2 was adjusted for household income, BMI, smoking status, alcohol consumption, physical activity, comorbidities (asthma, chronic obstructive pulmonary disease, cerebrovascular disease, hypertension, angina or myocardial infarction, congestive heart failure, diabetes mellitus and CTDs), CCI and medications. Covariates included in model 2 were selected based on a combination of clinical relevance, prior epidemiological evidence on bronchiectasis risk factors and associations observed in our data. Variables such as age and CCI, which showed significant associations in univariable analyses, were included, whereas variables like sex and household income, although not statistically significant, were included based on their established relevance in prior studies.67 36,38 Variables that could plausibly lie on the causal pathway between SLE and bronchiectasis were not adjusted to avoid bias from controlling for mediators. All selected covariates were retained in the model regardless of their statistical significance. The numbers of ED visits and hospitalisations divided by the sum of the follow-up duration (per 100 000 PY) were defined as the incidence of ED visits and hospitalisations, respectively. All tests were two-sided and a p value <0.05 was considered statistically significant. All statistical analyses were performed using SAS software V.9.4 (SAS Institute, Cary, North Carolina, USA) and R V.4.2.3 (R Foundation for Statistical Computing, Vienna, Austria). Results Baseline characteristics The baseline characteristics of the individuals (age, sex and type of insurance) exhibited a well-balanced distribution between the two cohorts (table 1). The SLE cohort had a higher rate of people with high household income (34.1% vs 30.9%, p<0.001) and people who did not smoke (78.4% vs 77.7%, p=0.022) than the matched cohort. Additionally, the SLE cohort showed a higher prevalence of hypertension (16.2% vs 13.8%, p<0.001), angina or myocardial infarction (4.7% vs 3.8%, p=0.018) and CTDs (12.1% vs 4.1%, p<0.001). A CCI score ≥2 was also higher in the SLE cohort (22.0% vs 16.8%, p<0.001). Systemic corticosteroids (8.9% vs 5.4%, p<0.001) and immunomodulators (3.8% vs 0.6%, p<0.001) were used significantly more frequently in the SLE cohort than in the matched cohort. Table 1Baseline characteristics of the study patientsVariableTotal(n=16 840)SLE cohort(n=3368)Matched cohort(n=13 472)P valueAge (years)>0.999 20–292565 (15.2)513 (15.2)2052 (15.2) 30–392295 (13.6)459 (13.6)1836 (13.6) 40–495980 (35.5)1196 (35.5)4784 (35.5) 50–593565 (21.2)713 (21.2)2852 (21.2) 60–691940 (11.5)388 (11.5)1552 (11.5) ≥70495 (2.9)99 (2.9)396 (2.9)Sex>0.999 Male4590 (27.3)918 (27.3)3672 (27.3) Female12 250 (72.7)2450 (72.7)9800 (72.7)Type of insurance>0.999 Self-employed health insurance5720 (34.0)1144 (34.0)4576 (34.0) Employee health insurance11 120 (66.0)2224 (66.0)8896 (66.0)Household income<0.001 Low3348 (19.9)579 (17.2)2769 (20.6) Middle8177 (48.6)1642 (48.8)6535 (48.5) High5315 (31.6)1147 (34.1)4168 (30.9)Body mass index0.356 Underweight751 (4.5)143 (4.3)608 (4.5) Normal7378 (43.8)1519 (45.1)5859 (43.5) Overweight3724 (22.1)739 (21.9)2985 (22.2) Obese4987 (29.6)967 (28.7)4020 (29.8)Smoking status0.022 Never smoker13 106 (77.8)2642 (78.4)10 464 (77.7) Ex-smoker1017 (6.0)226 (6.7)791 (5.9) Current smoker2717 (16.1)500 (14.9)2217 (16.5)Alcohol consumption (days/week)0.291 None10 277 (61.0)2091 (62.1)8186 (60.8) 1–46165 (36.6)1205 (35.8)4960 (36.8) ≥5398 (2.4)72 (2.1)326 (2.4)Physical activity (days/week)0.004 None10 571 (62.8)2031 (60.3)8540 (63.4) 1–45103 (30.3)1085 (32.2)4018 (29.8) ≥51166 (6.9)252 (7.5)914 (6.8)Comorbidities Pulmonary comorbidities Asthma1699 (10.1)337 (10.0)1362 (10.1)0.858 Chronic obstructive pulmonary disease609 (3.6)136 (4.0)473 (3.5)0.143 Cerebrovascular disease371 (2.2)79 (2.4)292 (2.2)0.529 Cardiovascular disease Hypertension2406 (14.3)546 (16.2)1860 (13.8)<0.001 Angina or myocardial infarction665 (4.0)157 (4.7)508 (3.8)0.018 Congestive heart failure230 (1.4)46 (1.4)184 (1.4)>0.999 Diabetes mellitus1353 (8.0)292 (8.7)1061 (7.9)0.129 Connective tissue diseases957 (5.7)406 (12.1)551 (4.1)<0.001CCI<0.001 0–113 835 (82.2)2626 (78.0)11 209 (83.2) ≥23005 (17.8)742 (22.0)2263 (16.8)Medication Systemic corticosteroid use1029 (6.1)300 (8.9)729 (5.4)<0.001 Immunomodulator208 (1.2)129 (3.8)79 (0.6)<0.001Data are presented as number (%).CCI, Charlson Comorbidity Index; SLE, systemic lupus erythematosus. Baseline characteristics of the study patients Data are presented as number (%). CCI, Charlson Comorbidity Index; SLE, systemic lupus erythematosus. Risk of bronchiectasis in individuals with SLE During a median follow-up duration of 12.8 years (IQR 10.0–16.0 years), the incidence rate of bronchiectasis was higher in the SLE cohort than in the matched cohort (374.76 vs 236.15 per 100 000 PY; p<0.001) (table 2). The cumulative incidence plot showed similar results (Gray’s test, p<0.001) (figure 2). Table 2Incidence rates and HR for bronchiectasis in the SLE and matched cohorts according to sociodemographic and lifestyle risk factorsVariableNumber of patientsCasesIncidence rate (/100 000 PY)Model 1Model 2HR (95% CI)P valueHR (95% CI)P valueOverall Matched cohort13 472402236.151 (ref)1 (ref) SLE cohort3368168374.761.57 (1.32 to 1.89)<0.0011.46 (1.22 to 1.76)<0.001Age (years) 20–39 Matched cohort38883672.131 (ref)1 (ref) SLE cohort97214105.041.48 (0.80 to 2.75)0.2121.60 (0.86 to 2.98)0.139 40–59 Matched cohort7636246254.971 (ref)1 (ref) SLE cohort1909100393.391.52 (1.21 to 1.92)<0.0011.47 (1.16 to 1.86)0.001 ≥60 Matched cohort1948120503.451 (ref)1 (ref) SLE cohort48754888.251.76 (1.28 to 2.43)<0.0011.58 (1.14 to 2.21)0.007 P for interaction0.7420.725Sex Male Matched cohort3672104221.701 (ref) SLE cohort91846364.821.64 (1.16 to 2.32)0.0061.41 (0.98 to 2.02)0.061 Female Matched cohort9800298241.651 (ref) SLE cohort2450122378.661.55 (1.26 to 1.92)<0.0011.47 (1.18 to 1.82)<0.001 P for interaction0.8250.712Type of insurance Self-employed Matched cohort4576161286.181 (ref)1 (ref) SLE cohort114466450.261.55 (1.17 to 2.07)0.0031.52 (1.14 to 2.04)0.005 Employee Matched cohort8896241211.451 (ref)1 (ref) SLE cohort2224102338.091.59 (1.26 to 2.01)<0.0011.45 (1.14 to 1.84)0.002 P for interaction0.9420.804Household income Low Matched cohort276972205.141 (ref)1 (ref) SLE cohort57923299.061.45 (0.90 to 2.31)0.1241.31 (0.80 to 2.14)0.287 Middle Matched cohort6535179218.011 (ref)1 (ref) SLE cohort164285390.891.78 (1.38 to 2.31)<0.0011.77 (1.36 to 2.30)<0.001 High Matched cohort4168151284.771 (ref)1 (ref) SLE cohort114760389.811.36 (1.01 to 1.83)0.0471.22 (0.90 to 1.66)0.201 P for interaction0.3820.280Body mass index Underweight Matched cohort60815199.921 (ref)1 (ref) SLE cohort1438431.012.15 (0.91 to 5.07)0.0811.98 (0.79 to 4.96)0.145 Normal Matched cohort5859171232.181 (ref)1 (ref) SLE cohort151982411.521.76 (1.36 to 2.30)<0.0011.57 (1.20 to 2.06)0.001 Overweight Matched cohort298597254.011 (ref)1 (ref) SLE cohort73935347.781.35 (0.92 to 1.99)0.1281.36 (0.92 to 2.02)0.123 Obese Matched cohort4020119233.831 (ref)1 (ref) SLE cohort96743331.221.41 (0.99 to 1.99)0.0561.34 (0.94 to 1.91)0.102 P for interaction0.5360.725Smoking status Never smoker Matched cohort10 464320240.571 (ref)1 (ref) SLE cohort2642131371.891.53 (1.25 to 1.88)<0.0011.44 (1.17 to 1.78)<0.001 Ex-smoker Matched cohort79131323.921 (ref)1 (ref) SLE cohort22615510.321.59 (0.86 to 2.94)0.1421.41 (0.72 to 2.75)0.316 Current smoker Matched cohort221751184.491 (ref)1 (ref) SLE cohort50022330.171.77 (1.07 to 2.91)0.0261.67 (1.00 to 2.80)0.052 P for interaction0.8720.847Alcohol consumption (days/week) None Matched cohort8186283273.121 (ref)1 (ref) SLE cohort2091114410.801.49 (1.20 to 1.86)<0.0011.39 (1.11 to 1.74)0.004 1–4 Matched cohort4960110175.251 (ref)1 (ref) SLE cohort120548296.421.67 (1.19 to 2.35)0.0031.57 (1.11 to 2.21)0.011 ≥5 Matched cohort3269233.891 (ref)1 (ref) SLE cohort726678.842.90 (1.03 to 8.16)0.0433.96 (1.24 to 12.71)0.021 P for interaction0.4260.408Physical activity (days/week) None Matched cohort8540253237.661 (ref)1 (ref) SLE cohort203196360.721.51 (1.20 to 1.91)<0.0011.45 (1.14 to 1.84)0.002 1–4 Matched cohort4018110212.131 (ref)1 (ref) SLE cohort108550337.621.57 (1.12 to 2.19)0.0081.36 (0.96 to 1.92)0.085 ≥5 Matched cohort91439327.191 (ref)1 (ref) SLE cohort25222646.061.97 (1.16 to 3.31)0.0111.82 (1.05 to 3.14)0.032 P for interaction0.6670.760Model 1 is the crude model.Model 2 is adjusted for household income, body mass index, smoking status, alcohol consumption, physical activity, comorbidities, CCI and medications.CCI, Charlson Comorbidity Index; ref, reference; SLE, systemic lupus erythematosus. Incidence rates and HR for bronchiectasis in the SLE and matched cohorts according to sociodemographic and lifestyle risk factors Model 1 is the crude model. Model 2 is adjusted for household income, body mass index, smoking status, alcohol consumption, physical activity, comorbidities, CCI and medications. CCI, Charlson Comorbidity Index; ref, reference; SLE, systemic lupus erythematosus. Cumulative incidence for bronchiectasis in the SLE and matched cohorts. SLE, systemic lupus erythematosus. Even after adjusting for confounders, the SLE cohort showed a 1.46-fold (95% CI 1.22 to 1.76) higher risk of developing bronchiectasis than the control cohort. Age, sex, type of insurance, household income, BMI, smoking status, alcohol consumption and physical activity did not affect the association between SLE and the risk of bronchiectasis (p value for interaction >0.05 for all in model 2). In a sensitivity analysis excluding individuals with other connective tissue diseases, the association remained robust (aHR 1.53, 95% CI 1.26 to 1.86; online supplemental table S1). Factors associated with incident bronchiectasis in individuals with SLE The factors associated with incident bronchiectasis in the SLE cohort are shown in table 3. In the multivariable analyses, increasing age (the highest adjusted HR was 25.08 (95% CI 7.62 to 82.53) for those ≥70 years) and asthma (adjusted HR 1.73 (95% CI 1.11 to 2.70)) were significant factors associated with an elevated risk of incident bronchiectasis. On the other hand, obesity (adjusted HR 0.56 (95% CI 0.38 to 0.82)) decreased the risk of incident bronchiectasis. Table 3Risk factors for bronchiectasis in patients with SLEVariableModel 1Model 2HR (95% CI)P valueHR (95% CI)P valueAge (years) 20–291 (ref)1 (ref) 30–392.70 (0.85 to 8.62)0.0933.05 (0.95 to 9.80)0.061 40–495.21 (1.88 to 14.45)0.0026.19 (2.18 to 17.61)<0.001 50–599.50 (3.43 to 26.25)<0.00111.81 (4.13 to 33.79)<0.001 60–6914.24 (5.10 to 39.76)<0.00117.64 (6.02 to 51.69)<0.001 ≥7021.53 (7.02 to 66.07)<0.00125.08 (7.62 to 82.53)<0.001Sex Male1 (ref)1 (ref) Female1.04 (0.74 to 1.46)0.8311.15 (0.73 to 1.82)0.549Type of insurance Self-employed health insurance1 (ref)1 (ref) Employee health insurance0.75 (0.55 to 1.02)0.0681.08 (0.78 to 1.49)0.654Household income Low1 (ref)1 (ref) Middle1.31 (0.83 to 2.08)0.2461.38 (0.87 to 2.21)0.174 High1.31 (0.81 to 2.12)0.2701.04 (0.64 to 1.70)0.874Body mass index Underweight1.05 (0.51 to 2.18)0.8901.73 (0.82 to 3.64)0.149 Normal1 (ref)1 (ref) Overweight0.84 (0.57 to 1.25)0.3910.69 (0.46 to 1.03)0.070 Obese0.80 (0.55 to 1.16)0.2400.56 (0.38 to 0.82)0.003Smoking status Never smoker1 (ref)1 (ref) Ex-smoker1.38 (0.81 to 2.36)0.2381.63 (0.87 to 3.04)0.125 Current smoker0.89 (0.57 to 1.40)0.6111.13 (0.66 to 1.93)0.656Alcohol consumption (days/week) None1 (ref)1 (ref) 1–40.72 (0.52 to 1.01)0.0580.99 (0.68 to 1.45)0.961 ≥51.67 (0.74 to 3.80)0.2201.35 (0.56 to 3.26)0.502Physical activity (days/week) None1 (ref)1 (ref) 1–40.93 (0.66 to 1.31)0.6891.03 (0.72 to 1.46)0.887 ≥51.78 (1.12 to 2.83)0.0151.28 (0.79 to 2.05)0.313Comorbidities Pulmonary comorbidities Asthma2.52 (1.69 to 3.75)<0.0011.73 (1.11 to 2.70)0.017 Chronic obstructive pulmonary disease2.81 (1.65 to 4.78)<0.0011.46 (0.82 to 2.60)0.199 Cerebrovascular disease1.49 (0.61 to 3.62)0.3820.71 (0.28 to 1.81)0.472 Cardiovascular disease Hypertension1.86 (1.31 to 2.65)<0.0011.10 (0.72 to 1.67)0.662 Angina or myocardial infarction1.63 (0.88 to 3.00)0.1190.88 (0.46 to 1.71)0.710 Congestive heart failure0.48 (0.07 to 3.46)0.4700.21 (0.03 to 1.51)0.120 Diabetes mellitus1.80 (1.15 to 2.82)0.0111.02 (0.63 to 1.66)0.946 Connective tissue diseases1.51 (0.98 to 2.31)0.0590.94 (0.55 to 1.60)0.813CCI 0–11 (ref)1 (ref) ≥22.07 (1.49 to 2.88)<0.0011.27 (0.83 to 1.96)0.277Medication Systemic corticosteroid use1.45 (0.90 to 2.34)0.1281.05 (0.63 to 1.75)0.868 Immunomodulator1.51 (0.74 to 3.08)0.2541.09 (0.48 to 2.50)0.841 Model 1 is the crude model.Model 2 is adjusted for household income, body mass index, smoking status, alcohol consumption, physical activity, comorbidities, CCI and medications.CCI, Charlson Comorbidity Index; ref, reference; SLE, systemic lupus erythematosus. Risk factors for bronchiectasis in patients with SLE Model 1 is the crude model. Model 2 is adjusted for household income, body mass index, smoking status, alcohol consumption, physical activity, comorbidities, CCI and medications. CCI, Charlson Comorbidity Index; ref, reference; SLE, systemic lupus erythematosus. Mortality and healthcare utilisation Individuals with both SLE and bronchiectasis had higher incidence rates of all-cause and respiratory-related mortality, hospitalisations and ED visits, compared with those with only SLE (p<0.05 for all) (figure 3). Comparison of all-cause mortality, ED visits and hospitalisations during follow-up between individuals with SLE and BE and individuals with SLE without BE. (A) All-cause mortality; (B) respiratory disease-related mortality; (C) all-cause ED visits and hospitalisations; (D) respiratory disease-related ED visits and hospitalisations. BE, bronchiectasis; ED, emergency department; SLE, systemic lupus erythematosus. Discussion This nationwide, population-based cohort study examined the association between SLE and subsequently diagnosed bronchiectasis using registry-based data. We observed that individuals with SLE had a higher incidence of clinically coded bronchiectasis compared with matched controls and that coexisting bronchiectasis was associated with increased healthcare utilisation and mortality during follow-up. These findings suggest that patients with SLE may be at increased risk of structural airway abnormalities recorded as bronchiectasis in administrative data. The association between SLE and bronchiectasis is likely multifactorial.1 2 Chronic immune dysregulation in SLE is associated with increased susceptibility to respiratory infections and sustained pulmonary inflammation, which may contribute to irreversible airway damage in these patients.3 39 Moreover, SLE-related pulmonary manifestations can lead to structural changes in the bronchial tree, predisposing patients to the development of bronchiectasis.4 40 These hypotheses are supported by previous case series and small cohort studies, although until now, evidence from large population-based cohorts has been rare.10,12 To the best of our knowledge, ours is the first nationwide representative longitudinal population-based study to show that SLE is associated with a 1.46-fold higher risk of bronchiectasis. Among the patients with SLE in this study, older age and the presence of asthma were found to increase the risk of bronchiectasis, reflecting the effects of age-related decline in immune function and chronic airway inflammation superimposed on SLE-related pulmonary damage. Furthermore, coexisting asthma could worsen compound epithelial damage and hypersecretion and thus make the local environment more susceptible to bronchiectasis. In contrast, obesity showed a protective association, which could be related to the so-called obesity paradox observed in chronic respiratory diseases, including chronic obstructive pulmonary disease and bronchiectasis. In a previous study that evaluated the association between BMI and bronchiectasis risk, BMI was negatively associated with the risk of developing bronchiectasis.41 It has been suggested that obesity might confer protective effects through leptin-mediated modulation of inflammatory responses or differences in treatment strategies.42 43 The increased mortality rate and healthcare utilisation of patients with SLE with bronchiectasis align with previous findings that patients with RA-bronchiectasis overlap experience a worse disease course than those with RA or bronchiectasis alone.9 44 45 Beyond simple addition, coexistence of those conditions could have synergistic negative effects by intensifying systemic and pulmonary inflammation, leading to higher disease activity and increasing infection risks. This concept could also be applicable to the overlap of SLE and bronchiectasis. The increased risk of bronchiectasis and its negative effects on the disease course of SLE underscore the importance of proactive respiratory monitoring in patients with SLE. Given the almost 1.5-fold higher incidence of bronchiectasis in patients with SLE, clinicians should maintain a low threshold for investigating new or worsening respiratory symptoms—ideally through targeted history-taking, pulmonary function testing and high-resolution CT when indicated. The risk is particularly elevated among older adults and those with coexisting asthma, so careful monitoring of pulmonary symptoms is crucial in older patients and in those with asthma. Early identification of bronchiectasis could allow the initiation of airway clearance strategies, tailored antimicrobial prophylaxis and immunomodulatory adjustments that could mitigate disease progression. Therefore, respiratory inflammatory symptoms, such as sputum production, in patients with SLE should never be overlooked, and efforts should be made to maintain sputum discharge and ensure airway clearance. Integrating routine respiratory risk assessment into SLE care pathways promises to reduce healthcare utilisation and improve long-term survival in this vulnerable population. Beyond general immune dysregulation observed in many autoimmune diseases, SLE is characterised by immune complex deposition, complement activation and a prominent type I interferon signature, all of which may contribute to chronic inflammatory injury in pulmonary tissues.46,49 Neutrophil extracellular trap formation, a key pathogenic feature in SLE, may further amplify local inflammatory cascades and tissue remodelling within the airways.50,53 In addition, SLE-associated microvascular involvement and the frequent use of immunosuppressive therapies may increase susceptibility to recurrent pulmonary insults.54 55 While these mechanisms remain speculative in the context of our registry-based study, they provide biologically plausible pathways that warrant further investigation. Our study has some limitations. First, there might be healthy user bias because our study was exclusively performed on people who received health screenings. Second, bronchiectasis was identified using ICD-10 diagnosis codes, so we might have missed subclinical or misclassified cases. In addition, because radiological images were not available for review, misclassification between conventional bronchiectasis and traction bronchiectasis associated with ILD cannot be completely excluded. Third, residual confounding cannot be ruled out despite adjustment for several known risk factors because certain clinical variables—such as pulmonary function test results, imaging data and specific medication adherence—were not available in the dataset. Fourth, this study was conducted exclusively in a Korean population, which could limit the generalisability of our findings to other ethnicities and healthcare systems. In conclusion, our results suggest that SLE is an independent risk factor for the development of bronchiectasis. Furthermore, individuals with both SLE and bronchiectasis had higher rates of mortality and healthcare utilisation than those without bronchiectasis. These findings underscore the importance of early recognition and comprehensive management of bronchiectasis in patients with SLE. Supplementary material The funders had no role in study design, data collection, analysis or interpretation, decision to publish or preparation of the manuscript. Footnotes Funding: This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) (RS-2025-00557268, RS-2020-NR049557, and RS-2026-25480547). This work was supported by the research fund of Hanyang University (HY-202500000001668). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Data availability free text: Data are available from the Korean National Health Insurance Service (NHIS), but restrictions apply to the availability of these data, which were used under licence for the current study and are therefore not publicly available. Researchers may apply for access to these data through the NHIS. Ethics approval: This study was approved by the Institutional Review Board of Chungbuk National University Hospital (IRB no. 2025-05-008). The requirement for informed consent was waived because the National Health Insurance Service database was constructed after anonymisation. Data availability statement Data may be obtained from a third party and are not publicly available. References Associated Data Supplementary Materials Data Availability Statement Data may be obtained from a third party and are not publicly available.